

PERSONAL INFORMATION

Stefano Cavalieri

📍 Head and Neck Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, via Venezian 1, 20133 Milan & Department of Oncology and Hemato-Oncology, University of Milan, via Santa Sofia 9/1, 20122 Milan

✉ stefano.cavalieri@istitutotumori.mi.it
stefano.cavalieri@unimi.it

Sex Male | Date of birth 06/01/1988 | Nationality Italian

WORK EXPERIENCE

From 11/2021

Researcher (“Ricercatore a tempo determinato, RTD-A”, non-tenure track appointment) and Medical Oncologist

Department of Oncology and Hemato-Oncology, University of Milan

Clinical activity at the Head and Neck Medical Oncology Department of the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

01/2020-10/2021

Medical Oncologist

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Head and Neck Medical Oncology Department

12/2014-12/2019

Resident in Medical Oncology

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Head and Neck Medical Oncology Department (since 11/2016) - Department of Medical Oncology

EDUCATION AND TRAINING

12/2019

Board Certificate in Medical Oncology

University of Milan - Fondazione IRCCS Istituto Nazionale dei Tumori, Milano (Italy).
Graduation 18th December 2019. 70/70 cum laude

Thesis *A big data-based analysis of radiosensitivity through transcriptomics and radiomics in head and neck cancer patients treated with multimodality curative approaches including radiotherapy*

02/2014

Italian Medical Licensing Examination

University of Milan, Milano (Italy)

10/2007–07/2013

Doctor of Medicine Degree

University of Milan, Milano (Italy). Graduation 19th July 2013. 110/110 cum laude

Thesis *Autologous hematopoietic stem cell transplantation in refractory Systemic Sclerosis and Crohn's disease: a single-center experience*

WORK ACTIVITIES

Research grants

- PI of the competitive grant “Decoding the tumor ecosystem heterogeneity of primary cancer and lymph node metastases through spatial analysis inferred from gene expression: a pilot study in resectable oral cavity squamous cell carcinoma” funded by the University of Milan (PSR, Piano di Sostegno alla Ricerca 2023)

- PI of the observational study “Retrospective analysis of the role of concomitant chemotherapy delivered with radiotherapy in the curative treatment of adenoid cystic carcinoma of the head and neck” at the Fondazione IRCCS Istituto Nazionale dei Tumori of Milan
- PI of the randomized controlled study “A multicentre randomised trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer” (ClinicalTrials.gov identifier: NCT05315570) at the study sponsor site (Fondazione IRCCS Istituto Nazionale dei Tumori of Milan). The BD4QoL project, in the frame of which this work is being conducted, has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 875192 (Project Coordinator prof. Lisa Licitra).

Awards

- 2021 "Enrico Belloni" Award - BCC Barlassina, Italy
- 2020 TRYTRAC program - Cancer Core Europe / Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
- 2018 ESMO Merit awards for the abstract “*Genomics features (GF) and integration with MRI radiomics features (RF) to develop a prognostic model in oral cavity squamous cell carcinoma (OSCC)*”, accepted as poster discussion

Editorial activity

Editor for the head and neck section of *Frontiers in Oncology*. Lead editor of the research topic titled “Diagnosis, Epidemiology and Treatment of Salivary Gland Carcinomas” edited by *Frontiers in Oncology*.

Co-editor of the research topic titled “Advances in Human-Papillomavirus-Related Squamous Cell Carcinoma: From Pathogenesis to Treatment” edited by *Cancers (Basel)*.

Peer reviewer of at least one manuscript for the following Journals: *British Journal of Cancer*, *Cancers (Basel)*, *Clinica Chimica Acta*, *European Journal of Cancer*, *ESMO Open*, *Frontiers in Oncology*, *Journal of Inflammation*, *Oncotargets*, *Oral Oncology*, *Tumori Journal*.

Invited oral presentations

- Conference “International Oral Cancer Congress 2025” (06-09/02/2025; hybrid event in New Dehli, India and online), lecture “Prognostic gene signatures for head and neck cancer patients”, lecture online 08/02/2025
- Conference “2nd international meeting on precision oncology and personalized medicine for head and neck cancer” (17-18/01/2025; evento in presenza a Heidelberg, Germania), session “Molecular landscape, multiomics and artificial intelligence”, lecture “Transcriptomics in head and neck cancer”, Heidelberg (Germania) 18/01/2025
- Conference “Grandangolo 2024 - Un anno di oncologia, 26a edizione” (19-21/12/2024; hybrid event in Genova and online), session “Tumori rari solidi dell’adulto”, lecture “Tumori cutanei rari non-melanoma”, Genova 21/12/2024
- Conference “Grandangolo 2024 - Un anno di oncologia, 26a edizione” (19-21/12/2024; hybrid event in Genova and online), session “Tumori rari solidi dell’adulto”, moderatore della session “Tumori testa-collo, cerebrali e tiroidei”, Genova 21/12/2024
- Conference “Il PDTA Ospedale-Territorio: Il percorso del paziente oncologico”, lecture “Il ruolo della digital-Health per l’integrazione ospedale-territorio”, Milano 28/11/2024
- Conference “Combinazioni terapeutiche – Ruolo sinergico delle differenti tipologie di trattamento”, lecture “Adroterapia ed inibitori del checkpoint immunologico nei tumori oligometastatici”, Milano 22/11/2024
- Conference “Young to young 2024, l’oncologia di domani” (11-12/10/2024; hybrid event in presenza a Genova e online), session “Altri tumori”, lecture “Tumori testa-collo”, Genova 11/10/2024
- Congress “L’immunoterapia in pillole 2024: novità e algoritmi terapeutici nella pratica clinica - Terza Edizione” (14-15/06/2024; hybrid event: Genova and online), lecture “Neoplasie della testa e collo - Novità dagli studi clinici e algoritmo terapeutico”, Genova 14/06/2024
- Course “Martedì dell’Ordine” - Ordine dei Medici Chirurghi e Odontoiatri (OMCeO) di Parma, “Progressi nel monitoraggio della qualità della vita dopo il trattamento oncologico. Ruolo della tecnologia in tasca al paziente”, lecture “BD4QoL: uno studio multicentrico randomizzato per il monitoraggio della qualità della vita nei pazienti curati per tumori del distretto testa-collo, basato su nuove tecnologie”, Parma 19/03/2024
- Course “Head and neck surgery academy 2024” (01-11/2024; hybrid event), webinar “Approccio clinico-diagnostico-terapeutico ai tumori ipofaringei e laringei”, lecture “Altre terapie non chirurgiche e risultati”, online 18/04/2024
- Congress “Health & Tech Summit- 6th International Conference - 6th International Conference” (12-14/12/2023; Paris, France), session “Where is really innovation? Oncology”, lecture “Big data for quality of life in head and neck cancer. The BD4QoL project”, Paris 13/12/2023
- Congress “Grandangolo 2023 - Un anno di oncologia, 25a edizione” (14-16/12/2023; hybrid event: Genova and online), session “Tumori rari solidi dell’adulto”, lecture “Tumori cutanei rari non-melanoma”, Genova 16/12/2023
- National Congress DMSCG (Dutch melanoma skin cancer group) Symposium 2023 (27/11/2023; hybrid event: Ede, The Netherlands and online), lecture “Skin adnexal carcinomas”, online 27/11/2023

- National Congress of the “Asociacion Argentina de Oncologia Clinica” (08-10/11/2023; hybrid event: Buenos Aires, Argentina and online), session “Nasopharyngeal carcinoma”, lecture “Update on the treatment of advanced nasopharyngeal carcinoma. Role of immunotherapy”, online 10/11/2023
- Congress AIOM (Associazione Italiana di Oncologia Medica) “XXV Congresso nazionale” (10-12/11/2023; Roma), session “Altre comunicazioni orali”, oral presentation “LAT1 in head and neck squamous cell carcinoma (HNSCC)”, Roma, 11/11/2023
- SuPerTreat plenary meeting 2023, lectures “Big data in head and neck cancer and unmet needs”, “Clinical data harmonization” and “Clinical scenarios”, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 07/07/2023
- Webinar AIRO (Associazione Italiana Radioterapia e Oncologia clinica) “Minor Salivary Gland Tumors: A Mouth-Watering Contouring Workshop”, lecture “Trattamento - Terapia sistemica”, online 30/06/2023
- Conference IFHNOS (International Federation of Head and Neck Oncologic Societies) 2023, lecture “Big data in QoL in HNC - the BD4QoL programme” in the session “Big data in head and neck cancer”, lecture “Big Data & Artificial Intelligence in head and neck cancer” in the session “Towards precision oncology in head and neck cancer: critical issues”, lecture “Biomarkers in head and neck cancer” in the session “Genomic Profiling of HNSCC for Targeted Therapy - clinical utility and impact”, chairman of the session “Contribution of real world data to the field”, Roma 22/06/2023
- Lecture “Very rare: Adnexal tumors” in the session dedicated to “Non-skin melanoma, adnexal tumours and Merkel cell carcinoma” at the “ESMO Sarcoma and rare cancer 2023 Annual Congress”, Lugano (Switzerland), 20/03/2023
- Conference “Il paziente con cancro della bocca”, session “Trattamenti non chirurgici e riabilitazione del paziente con cancro della bocca”, lecture “L’analisi genomica in oncologia orale”, Ospedale San Paolo, Milano, 27/02/2023
- Lectures “Decisioni cliniche: La malattia localizzata - Tumori della testa e del collo” e “Decisioni cliniche: La malattia avanzata - Tumori della testa e del collo” at the course “Decidere in Oncologia” organizzato da Accademia Nazionale di Medicina”, Milan 23-24/01/2023
- Lecture “Big data in oncologia cervico-cefalica” at the 11th meeting of the Otorhinolaryngology group of Lombardy titled “Intelligenza artificiale, omics e big data in oncologia testa e collo: un panorama in rapida evoluzione”, Milan 09/2022
- Lectures at managerial course “Rivalidazione della Formazione Manageriale” organized by ECOLE (Enti Confindustriali Lombardi per l’Education). 05/2021 and 12/2021
- ESO-ESMO-RCE Clinical Update on Rare Adult Solid Cancers, Lecture “Cutaneous adnexal malignancies”. 6th (2021), 5th (2020), 4th (2019)
- Laryngeal cancer today 2019 – Consensus conference. Milan, 22/02/2019
- Grandangolo in Oncologia. Focus su terapie di supporto 2018. Bologna, 07/05/2018
- ECHNO (European Congress on Head and Neck Oncology) 8th Edition, Rome, 11/04/2018. Abstract selected as oral presentation in the “Young Scientists Forum” session
- IMI (Intergruppo Melanoma Italiano - Italian Melanoma Network) Master Course, Milan, 26/11/2016
- IMI 22nd meeting, Ragusa, 15/11/2016. Abstract selected as oral presentation

PUBLICATIONS

- Author of 66 abstracts presented at international or national scientific meetings, 4 book chapters. Author of the following full articles:
 1. **Cavalieri S**, Di Guardo L, Cimminiello C, Bono A, Tolomio E, Colombetti A, Valeri B, Di Tolla G, de Braud F, Del Vecchio M. Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience. *Tumori*. 2016 Oct 13;102(5):501-507. doi: 10.5301/tj.5000539. Epub 2016 Jul 27. PMID: 27470608
 2. **Cavalieri S**, Di Guardo L, Cossa M, Cimminiello C, Del Vecchio M. Unusual Skin Carcinomas Induced by BRAF Inhibitor for Metastatic Melanoma: A Case Report. *J Clin Diagn Res*. 2017 Jul;11(7):XD06-XD08. doi: 10.7860/JCDR/2017/26881.10200. Epub 2017 Jul 1. PMID: 28893027; PMCID: PMC5583902
 3. Resteghini C, **Cavalieri S**, Galbiati D, Granata R, Alfieri S, Bergamini C, Bossi P, Licitra L, Locati LD. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients. *Best Pract Res Clin Endocrinol Metab*. 2017 Jun;31(3):349-361. doi: 10.1016/j.beem.2017.04.012. Epub 2017 May 10. PMID: 28911730
 4. **Cavalieri S**, Morelli D, Martinetti A, Galli G, Nichetti F, de Braud F, Platania M. Clinical implications for pro-GRP in small cell lung cancer. A single center experience. *Int J Biol Markers*. 2018 Jan;33(1):55-61. doi: 10.5301/ijbm.5000305. PMID: 28967066
 5. **Cavalieri S**, Stathis A, Fabbri A, Sonzogni A, Perrone F, Tamborini E, Pelosi G, de Braud F, Platania M. Uncommon somatic mutations in metastatic NUT midline carcinoma. *Tumori*. 2017 Nov 15;103(Suppl. 1):e5-e8. doi: 10.5301/tj.5000685. PMID: 28967088
 6. Alfieri S, **Cavalieri S**, Licitra L. Immunotherapy for recurrent/metastatic head and neck cancer. *Curr Opin Otolaryngol Head Neck Surg*. 2018 Apr;26(2):152-156. doi: 10.1097/MOO.0000000000000448. PMID: 29432222
 7. Galli G, Bregni G, **Cavalieri S**, Porcu L, Baili P, Hade A, Di Salvo F, Sant M, Agresti R, Gennaro M, Folli S, De Santis

- MC, Paolini B, Carcangiu ML, de Braud F, Di Cosimo S. Neoadjuvant Chemotherapy Exerts Selection Pressure Towards Luminal Phenotype Breast Cancer. *Breast Care (Basel)*. 2017 Dec;12(6):391-394. doi: 10.1159/000479582. Epub 2017 Dec 12. PMID: 29456471; PMCID: PMC5803695
8. Marconcini R, Spagnolo F, Stucci LS, Ribero S, Marra E, Rosa F, Picasso V, Di Guardo L, Cimminiello C, **Cavalieri S**, Orgiano L, Tanda E, Spano L, Falcone A, Queirolo P; Italian Melanoma Intergroup (IMI). Current status and perspectives in immunotherapy for metastatic melanoma. *Oncotarget*. 2018 Jan 3;9(15):12452-12470. doi: 10.18632/oncotarget.23746. PMID: 29552325; PMCID: PMC5844761
 9. **Cavalieri S**, Rivoltini L, Bergamini C, Locati LD, Licitra L, Bossi P. Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs. *Cancer Treat Rev*. 2018 Apr;65:78-86. doi: 10.1016/j.ctrv.2018.03.003. Epub 2018 Mar 20. PMID: 29574334
 10. **Cavalieri S**, Cosmai L, Genderini A, Nebuloni M, Tosoni A, Favales F, Pistillo P, Bergamini C, Bossi P, Licitra L, Locati LD, Alfieri S. Lenvatinib-induced renal failure: two first-time case reports and review of literature. *Expert Opin Drug Metab Toxicol*. 2018 Apr;14(4):379-385. doi: 10.1080/17425255.2018.1461839. Epub 2018 Apr 13. PMID: 29617171
 11. Resteghini C, Perrone F, Miceli R, Bergamini C, Alfieri S, Orlandi E, Guzzo M, Granata R, Galbiati D, **Cavalieri S**, Locati L, Licitra L, Bossi P. Prognostic role of PIK3CA and TP53 in human papillomavirus-negative oropharyngeal cancers. *Tumori*. 2018 Jun;104(3):213-220. doi: 10.1177/0300891618765558. Epub 2018 Apr 18. PMID: 29714670
 12. **Cavalieri S**, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, Granata R, Alfieri S, Resteghini C, Galbiati D, Busico A, Paielli N, Patuzzo R, Maurichi A, Gallino G, Ruggeri R, Mariani L, Palla M, Licitra L, Bossi P. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. *Eur J Cancer*. 2018 Jul;97:7-15. doi: 10.1016/j.ejca.2018.04.004. Epub 2018 May 4. PMID: 29734047
 13. Ripamonti CI, Antonuzzo A, Bossi P, **Cavalieri S**, Roila F, Fatigoni S. Fatigue, a major still underestimated issue. *Curr Opin Oncol*. 2018 Jul;30(4):219-225. doi: 10.1097/CCO.0000000000000451. PMID: 29877886
 14. van Boxtel W, Locati LD, van Engen-van Grunsven ACH, Bergamini C, Jonker MA, Fiets E, **Cavalieri S**, Tooten S, Bos E, Quattrone P, Verhaegh GW, Schalken JA, Licitra L, van Herpen CML; PALGA Group. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma. *Eur J Cancer*. 2019 Mar;110:62-70. doi: 10.1016/j.ejca.2018.12.035. Epub 2019 Feb 13. PMID: 30771738
 15. Mariani G, Galli G, **Cavalieri S**, Valagussa P, Bianchi GV, Capri G, Cresta S, Ferrari L, Damian S, Duca M, de Braud F, Moliterni A. Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study. *Breast J*. 2019 Mar;25(2):237-242. doi: 10.1111/tbj.13197. Epub 2019 Feb 27. PMID: 30810258
 16. Galli G, **Cavalieri S**, Di Guardo L, Cimminiello C, Nichetti F, Corti F, Garcia MA, Pappalardi B, Fallai C, de Braud F, Platania M, Del Vecchio M. Combination of Immunotherapy and Brain Radiotherapy in Metastatic Melanoma: A Retrospective Analysis. *Oncol Res Treat*. 2019;42(4):186-194. doi: 10.1159/000497211. Epub 2019 Mar 5. PMID: 30836373
 17. **Cavalieri S**, Platini F, Bergamini C, Resteghini C, Galbiati D, Bossi P, Perrone F, Tamborini E, Quattrone P, Licitra L, Locati LD, Alfieri S. Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities? *Expert Opin Investig Drugs*. 2019 May;28(5):435-443. doi: 10.1080/13543784.2019.1598376. Epub 2019 Apr 4. PMID: 30897975
 18. **Cavalieri S**, Busico A, Capone I, Conca E, Dalleria E, Quattrone P, Licitra L, Pruner G, Bossi P, Perrone F. Identification of potentially druggable molecular alterations in skin adnexal malignancies. *J Dermatol*. 2019 Jun;46(6):507-514. doi: 10.1111/1346-8138.14889. Epub 2019 Apr 30. PMID: 31038235
 19. Depenni R, Cossu Rocca M, Ferrari D, Azzarello G, Baldessari C, Alù M, Nolè F, Codecà C, Boscolo G, Piccininni M, **Cavalieri S**, Bossi P. Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting. *Eur J Cancer*. 2019 Jul;115:4-12. doi: 10.1016/j.ejca.2019.03.022. Epub 2019 May 10. PMID: 31082692
 20. **Cavalieri S**, Perrone F, Milione M, Bianco A, Alfieri S, Locati LD, Bergamini C, Resteghini C, Galbiati D, Platini F, Licitra L, Bossi P. PD-L1 Expression in Unresectable Locally Advanced or Metastatic Skin Squamous Cell Carcinoma Treated with Anti-Epidermal Growth Factor Receptor Agents. *Oncology*. 2019;97(2):112-118. doi: 10.1159/000500246. Epub 2019 May 21. PMID: 31112973
 21. Locati LD, **Cavalieri S**, Bergamini C, Resteghini C, Alfieri S, Calareso G, Bossi P, Perrone F, Tamborini E, Quattrone P, Granata R, Galbiati D, Platini F, Orlandi E, Mariani L, Licitra L. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. *Head Neck*. 2019 Oct;41(10):3670-3676. doi: 10.1002/hed.25891. Epub 2019 Jul 29. PMID: 31355973
 22. Locati LD, Serafini MS, Iannò MF, Carenzo A, Orlandi E, Resteghini C, **Cavalieri S**, Bossi P, Canevari S, Licitra L, De Cecco L. Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma. *Cancers (Basel)*. 2019 Jul 26;11(8):1057. doi: 10.3390/cancers11081057. PMID: 31357501; PMCID: PMC6721309
 23. Orlandi E, **Cavalieri S**, Granata R, Nicolai P, Castelnuovo P, Piazza C, Schreiber A, Turri-Zanoni M, Quattrone P, Miceli R, Infante G, Sessa F, Facco C, Calareso G, Iacovelli NA, Mattavelli D, Paderno A, Resteghini C, Locati LD, Licitra L, Bossi P. Locally advanced epithelial sinonasal tumors: The impact of multimodal approach. *Laryngoscope*. 2020 Apr;130(4):857-865. doi: 10.1002/lary.28202. Epub 2019 Aug 1. PMID: 31369156
 24. Bonomo P, Paderno A, Mattavelli D, Zenda S, **Cavalieri S**, Bossi P. Quality Assessment in Supportive Care in Head and Neck Cancer. *Front Oncol*. 2019 Sep 18;9:926. doi: 10.3389/fonc.2019.00926. PMID: 31620372; PMCID: PMC6759470
 25. Di Cosimo S, Appierto V, Silvestri M, Pruner G, Vingiani A, Perrone F, Busico A, Folli S, Scaperrotta G, de Braud FG, Bianchi GV, **Cavalieri S**, Daidone MG, Dugo M. Targeted-Gene Sequencing to Catch Triple Negative Breast Cancer Heterogeneity before and after Neoadjuvant Chemotherapy. *Cancers (Basel)*. 2019 Nov 8;11(11):1753. doi:

- 10.3390/cancers11111753. PMID: 31717320; PMCID: PMC6895966
26. Bergamini C, **Cavalieri S**, Sanguineti G, Farneti A, Licitra L. Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report. *Oxf Med Case Reports*. 2019 Oct 31;2019(10):omz102. doi: 10.1093/omcr/omz102. PMID: 31772741; PMCID: PMC6822604
 27. Locati LD, Galbiati D, Calareso G, Alfieri S, Singer S, **Cavalieri S**, Bergamini C, Bossi P, Orlandi E, Resteghini C, Platini F, Granata R, Quattrone P, Mancinelli M, Mariani L, Lo Vullo S, Licitra LF. Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. *Cancer*. 2020 Jan 1;126(9):1888-1894. doi: 10.1002/cncr.32754. Epub 2020 Feb 7. PMID: 32031693
 28. Galbiati D, **Cavalieri S**, Alfieri S, Resteghini C, Bergamini C, Orlandi E, Platini F, Locati L, Giacomelli L, Licitra L, Bossi P. Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. *Drugs Context*. 2019 Dec 19;8:212611. doi: 10.7573/dic.212611. PMID: 32158481; PMCID: PMC7048124
 29. Keek S, Sanduleanu S, Wesseling F, de Roest R, van den Brekel M, van der Heijden M, Vens C, Giuseppina C, Licitra L, Scheckenbach K, Vergeer M, Leemans CR, Brakenhoff RH, Nauta I, **Cavalieri S**, Woodruff HC, Poli T, Leijenaar R, Hoebbers F, Lambin P. Computed tomography-derived radiomic signature of head and neck squamous cell carcinoma (peri)tumoral tissue for the prediction of locoregional recurrence and distant metastasis after concurrent chemo-radiotherapy. *PLoS One*. 2020 May 22;15(5):e0232639. doi: 10.1371/journal.pone.0232639. Erratum in: *PLoS One*. 2020 Jul 28;15(7):e0237048. PMID: 32442178; PMCID: PMC7244120
 30. Locati L, **Cavalieri S***, Dal Maso L, Busco S, Anderson LA, Botta L, Bento MJ, Carulla M, Chirlaque López MD, Fusco M, Guevara M, Innos K, Børge Johannesen T, Micallef R, Minicozzi P, Panato C, Petrova D, Rubio-Casadevall J, Smailyte G, Francesca Vitale M, Trama A; RARECAREnet Working Group. Rare thyroid malignancies in Europe: Data from the information network on rare cancers in Europe (RARECAREnet). *Oral Oncol*. 2020 Sep;108:104766. doi: 10.1016/j.oraloncology.2020.104766. Epub 2020 May 23. PMID: 32454415
 31. **Cavalieri S**, Licitra L. Induction chemotherapy is the best timekeeper in nasopharyngeal carcinoma. *Cancer*. 2020 Aug 15;126(16):3624-3626. doi: 10.1002/cncr.32971. Epub 2020 Jun 4. PMID: 32497251
 32. **Cavalieri S**, Mariani L, Vander Poorten V, Van Breda L, Cau MC, Lo Vullo S, Alfieri S, Resteghini C, Bergamini C, Orlandi E, Calareso G, Clement P, Hauben E, Platini F, Bossi P, Licitra L, Locati LD. Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. *Eur J Cancer*. 2020 Sep;136:35-42. doi: 10.1016/j.ejca.2020.05.013. Epub 2020 Jul 3. PMID: 32629365
 33. **Cavalieri S**, Orlandi E, Ivaldi E, Bergamini C, Alfieri S, Iacovelli NA, Ingargiola R, Resteghini C, Platini F, Apollonio G, Beninato T, Incandela F, Fontanella W, Bresciani L, Giannini L, Piazza C, Licitra L, Locati LD. Management of loco-regionally advanced squamous laryngeal cancer in elderly patients. *Eur Arch Otorhinolaryngol*. 2021 Mar;278(3):771-779. doi: 10.1007/s00405-020-06179-1. Epub 2020 Jul 12. PMID: 32656672
 34. Bergamini C, **Cavalieri S**, Casella T, Lanocita R, Alfieri S, Resteghini C, Platini F, Orlandi E, Locati LD, Marchianò A, Licitra L. Local therapies for liver metastases of rare head and neck cancers: a monoinstitutional case series. *Tumori*. 2021 Jun;107(3):188-195. doi: 10.1177/0300891620952844. Epub 2020 Sep 14. PMID: 32924878
 35. Bologna M, Corino V, Calareso G, Tenconi C, Alfieri S, Iacovelli NA, Cavallo A, **Cavalieri S**, Locati L, Bossi P, Romanello DA, Ingargiola R, Rancati T, Pignoli E, Sdao S, Pecorilla M, Facchinetti N, Trama A, Licitra L, Mainardi L, Orlandi E. Baseline MRI-Radiomics Can Predict Overall Survival in Non-Endemic EBV-Related Nasopharyngeal Carcinoma Patients. *Cancers (Basel)*. 2020 Oct 13;12(10):2958. doi: 10.3390/cancers12102958. PMID: 33066161; PMCID: PMC7601980
 36. Iacovelli NA, Cicchetti A, Cavallo A, Alfieri S, Locati L, Ivaldi E, Ingargiola R, Romanello DA, Bossi P, **Cavalieri S**, Tenconi C, Meroni S, Calareso G, Guzzo M, Piazza C, Licitra L, Pignoli E, Carlo F, Orlandi E. Role of IMRT/VMAT-Based Dose and Volume Parameters in Predicting 5-Year Local Control and Survival in Nasopharyngeal Cancer Patients. *Front Oncol*. 2020 Sep 24;10:518110. doi: 10.3389/fonc.2020.518110. PMID: 33072562; PMCID: PMC7541899
 37. **Cavalieri S**, De Cecco L, Brakenhoff RH, Serafini MS, Canevari S, Rossi S, Lanfranco D, Hoebbers FJP, Wesseling FWR, Keek S, Scheckenbach K, Mattavelli D, Hoffmann T, López Pérez L, Fico G, Bologna M, Nauta I, Leemans CR, Trama A, Klausch T, Berkhof JH, Tountopoulos V, Shefi R, Mainardi L, Mercalli F, Poli T, Licitra L; BD2Decide Consortium. Development of a multiomics database for personalized prognostic forecasting in head and neck cancer: The Big Data to Decide EU Project. *Head Neck*. 2021 Feb;43(2):601-612. doi: 10.1002/hed.26515. Epub 2020 Oct 27. PMID: 33107152
 38. Peraldo-Neia C, Ostano P, Mello-Grand M, Guana F, Gregnanin I, Boschi D, Oliaro-Bosso S, Pippione AC, Carenzo A, De Cecco L, **Cavalieri S**, Micali A, Perrone F, Averono G, Bagnasacco P, Dosdegani R, Masini L, Krengli M, Aluffi-Valletti P, Valente G, Chiorino G. AKR1C3 is a biomarker and druggable target for oropharyngeal tumors. *Cell Oncol (Dordr)*. 2021 Apr;44(2):357-372. doi: 10.1007/s13402-020-00571-z. Epub 2020 Nov 19. PMID: 33211282
 39. Romanello DA, Imamguliyeva Z, **Cavalieri S**, Viscioni B, Gandola L, Iannalfi A, Iacovelli NA, Licitra L, Guzzo M, Piazza C, Lombardi D, Diletto B, Quattrone P, Calareso G, Locati LD, Orlandi E. Multidisciplinary Management of Radiation-Induced Salivary Gland Carcinomas in the Modern Radiotherapy Era. *Cancers (Basel)*. 2020 Dec 14;12(12):3769. doi: 10.3390/cancers12123769. PMID: 33327563
 40. **Cavalieri S**, Filippini DM, Ottini A, Bergamini C, Resteghini C, Colombo E, Lombardo R, Nuzzolese I, Alfieri S, Licitra L, Locati LD. Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies. *Explor Target Antitumor Ther*. 2021;2(6):522-542. doi: 10.37349/etat.2021.00062. Epub 2021 Dec 31. PMID: 36046116
 41. Platini F, **Cavalieri S**, Alfieri S, Bergamini C, Resteghini C, Bottiglieri A, Colombo E, Mazzeo L, Licitra L, Paolini B, Seregini E, Locati LD. Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib. *Endocrine*. 2021 Sep;73(3):641-647. doi: 10.1007/s12020-021-02702-4. Epub 2021 Apr 2. PMID: 33797698
 42. Filippini DM, Gatti M, Di Martino V, **Cavalieri S**, Fusaroli M, Ardizzoni A, Raschi E, Licitra L. Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance

- analysis. *Int J Cancer*. 2021 Aug 1;149(3):675-683. doi: 10.1002/ijc.33592. Epub 2021 May 4. PMID: 33844854
43. **Cavalieri S**, Colombo E, Bottiglieri A, Massa G, Platini F, Ottini A, Filippini DM, Zattarin E, Bergamini C, Resteghini C, Alfieri S, Di Martino V, Tiraferri V, Locati LD, Licitra L. Monitoring patients with head and neck cancer for flu-like symptoms during the COVID-19 pandemic. *Tumori*. 2022 Jun;108(3):240-249. doi: 10.1177/03008916211007940. Epub 2021 Apr 13. PMID: 33849307
 44. **Cavalieri S**, Licitra L. Next generation platinum salt in nasopharyngeal carcinoma. *Lancet Oncol*. 2021 May;22(5):577-578. doi: 10.1016/S1470-2045(21)00182-0. Epub 2021 Apr 12. PMID: 33857413
 45. Bergamini C, Ferris RL, Xie J, Mariani G, Ali M, Holmes WC, Harrington K, Psyrris A, **Cavalieri S**, Licitra L. Bleeding complications in patients with squamous cell carcinoma of the head and neck. *Head Neck*. 2021 Sep;43(9):2844-2858. doi: 10.1002/hed.26772. Epub 2021 Jun 12. PMID: 34117666
 46. Keek SA, Wesseling FWR, Woodruff HC, van Timmeren JE, Nauta IH, Hoffmann TK, **Cavalieri S**, Calareso G, Primakov S, Leijenaar RTH, Licitra L, Ravanelli M, Scheckenbach K, Poli T, Lanfranco D, Vergeer MR, Leemans CR, Brakenhoff RH, Hoebbers FJP, Lambin P. A Prospectively Validated Prognostic Model for Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck Based on Radiomics of Computed Tomography Images. *Cancers (Basel)*. 2021 Jun 29;13(13):3271. doi: 10.3390/cancers13133271. PMID: 34210048
 47. Iacovelli NA, Ingargiola R, Facchinetti N, Franceschini M, Romanello DA, Bossi P, Bergamini C, Alfieri S, **Cavalieri S**, Baron G, Aldini G, Locati L, Orlandi E. A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy of Aqualief™ Mucoadhesive Tablets in Head and Neck Cancer Patients Who Developed Radiation-Induced Xerostomia. *Cancers (Basel)*. 2021 Jul 10;13(14):3456. doi: 10.3390/cancers13143456. PMID: 34298670
 48. Cavallo A, Iacovelli NA, Facchinetti N, Rancati T, Alfieri S, Giandini T, Cicchetti A, Fallai C, Ingargiola R, Licitra L, Locati L, **Cavalieri S**, Pignoli E, Romanello DA, Valdagni R, Orlandi E. Modelling Radiation-Induced Salivary Dysfunction during IMRT and Chemotherapy for Nasopharyngeal Cancer Patients. *Cancers (Basel)*. 2021 Aug 6;13(16):3983. doi: 10.3390/cancers13163983. PMID: 34439136
 49. **Cavalieri S**, Ronchi S, Barcellini A, Bonora M, Vischioni B, Vitolo V, Villa R, Del Vecchio M, Licitra L, Orlandi E. Toxicity of carbon ion radiotherapy and immune checkpoint inhibitors in advanced melanoma. *Radiother Oncol*. 2021 Nov;164:1-5. doi: 10.1016/j.radonc.2021.08.021. Epub 2021 Sep 8. PMID: 34506831
 50. **Cavalieri S**, Locati LD, Licitra L. An Old but Still Unanswered Question in Recurrent or Metastatic Salivary Duct Carcinoma. *JCO Precis Oncol*. 2021 Nov;5:1526-1527. doi: 10.1200/PO.21.00262. PMID: 34994640
 51. Locati LD, **Cavalieri S**, Bergamini C, Resteghini C, Colombo E, Calareso G, Mariani L, Quattrone P, Alfieri S, Bossi P, Platini F, Capone I, Licitra L. Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial. *J Clin Oncol*. 2021 Dec 20;39(36):4061-4068. doi: 10.1200/JCO.21.00468. Epub 2021 Oct 1. PMID: 34597119
 52. Riva G, Vischioni B, Gandini S, **Cavalieri S**, Ronchi S, Barcellini A, Bonora M, Chalaszczyk A, Ingargiola R, Vitolo V, Fiore MR, Iannalfi A, Orlandi E. Particle Beam Therapy Tolerance and Outcome on Patients with Autoimmune Diseases: A Single Institution Matched Case-Control Study. *Cancers (Basel)*. 2021 Oct 15;13(20):5183. doi: 10.3390/cancers13205183. PMID: 34680331
 53. **Cavalieri S**, Serafini MS, Carenzo A, Canevari S, Brakenhoff RH, Leemans CR, Nauta IH, Hoebbers F, van den Hout MFCM, Scheckenbach K, Hoffmann TK, Ardighieri L, Poli T, Quattrone P, Locati LD, Licitra L, De Cecco L. Clinical Validity of a Prognostic Gene Expression Cluster-Based Model in Human Papillomavirus-Positive Oropharyngeal Carcinoma. *JCO Precis Oncol*. 2021 Oct 27;5:PO.21.00094. doi: 10.1200/PO.21.00094. eCollection 2021. PMID: 34738049
 54. Loap P, Vischioni B, Bonora M, Ingargiola R, Ronchi S, Vitolo V, Barcellini A, Goanta L, De Marzi L, Dendale R, Pacelli R, Locati L, Calugaru V, Mammar H, **Cavalieri S**, Kirova Y, Orlandi E. Biological Rationale and Clinical Evidence of Carbon Ion Radiation Therapy for Adenoid Cystic Carcinoma: A Narrative Review. *Front Oncol*. 2021 Nov 30;11:789079. doi: 10.3389/fonc.2021.789079. eCollection 2021. PMID: 34917512
 55. Locati LD, Serafini MS, Carenzo A, Canevari S, Perrone F, Orlandi E, Delbue S, **Cavalieri S**, Berzeri G, Pichiecchio A, Licitra LF, Marchioni E, De Cecco L. Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report. *Front Oncol*. 2022 Jan 10;11:799453. doi: 10.3389/fonc.2021.799453. eCollection 2021. PMID: 35083153
 56. Lenoci D, Carenzo A, **Cavalieri S**, Pistore F, Serafini MS, Bossi P, Schmitz S, Machiels JP, Licitra LF, De Cecco L. Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials. *Oral Oncol*. 2022 Mar;126:105756. doi: 10.1016/j.oraloncology.2022.105756. Epub 2022 Feb 2. PMID: 35121395
 57. **Cavalieri S**, Nuzzolese I, Licitra L. Which future for de-intensified treatments in HPV-related oropharyngeal carcinoma? *Semin Oncol*. 2022 Oct;49(5):405-408. doi: 10.1053/j.seminoncol.2022.09.007. Epub 2022 Sep 29. PMID: 36241485
 58. **Cavalieri S**, Serafini MS, Carenzo A, Canevari S, Lenoci D, Pistore F, Miceli R, Vecchio S, Ferrari D, Moro C, Sponghini A, Caldara A, Rocca MC, Secondino S, Moretti G, Denaro N, Caponigro F, Vaccher E, Rinaldi G, Ferraù F, Bossi P, Licitra L, De Cecco L. An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer. *Cells*. 2022 Oct 10;11(19):3176. doi: 10.3390/cells11193176. PMID: 36231138
 59. Zeng PYF, Cecchini MJ, Barrett JW, Shammash-Toma M, De Cecco L, Serafini MS, **Cavalieri S**, Licitra L, Hoebbers F, Brakenhoff RH, Leemans CR, Scheckenbach K, Poli T, Wang X, Liu X, Laxague F, Prisman E, Poh C, Bose P, Dort JC, Shaikh MH, Ryan SEB, Dawson A, Khan MI, Howlett CJ, Stecho W, Plantinga P, Daniela da Silva S, Hier M, Khan H, MacNeil D, Mendez A, Yoo J, Fung K, Lang P, Winquist E, Palma DA, Ziai H, Amelio AL, Li SS, Boutros PC, Mymryk JS, Nichols AC. Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. *EBioMedicine*. 2022 Dec;86:104373. doi: 10.1016/j.ebiom.2022.104373. Epub 2022 Nov 25.

PMID: 36442320

60. **Cavalieri S**, Bossi P, Infante G, Miceli R, Iacovelli NA, Ivaldi E, Locati LD, Bergamini C, Resteghini C, Nuzzolese I, Alfieri S, Colombo E, Ingargiola R, Franceschini M, Calareso G, Licitra L, Orlandi E. The Interplay between Age and Viral Status in EBV-Related Nasopharyngeal and HPV-Related Oropharyngeal Carcinoma Patients. *Cancers (Basel)*. 2022 Dec 14;14(24):6170. doi: 10.3390/cancers14246170. PMID: 36551656
61. **Cavalieri S**, Nuzzolese I, Ottini A, Bergamini C, Resteghini C, Colombo E, Alfieri S, Quattrone P, Calareso G, Iacovelli NA, Franceschini M, Licitra L. HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients. *Front Oncol*. 2023 Jan 17;12:1096068. doi: 10.3389/fonc.2022.1096068. eCollection 2022. PMID: 36733354
62. **Cavalieri S**, Vener C, LeBlanc M, Lopez-Perez L, Fico G, Resteghini C, Monzani D, Marton G, Pravettoni G, Moreira-Soares M, Filippidou DE, Almeida A, Bilbao A, Mehanna H, Singer S, Thomas S, Lacerenza L, Manfuso A, Copelli C, Mercalli F, Frigessi A, Martinelli E, Licitra L; BD4QoL Consortium. A multicenter randomized trial for quality of life evaluation by non-invasive intelligent tools during post-curative treatment follow-up for head and neck cancer: Clinical study protocol. *Front Oncol*. 2023 Jan 31;13:1048593. doi: 10.3389/fonc.2023.1048593. eCollection 2023. PMID: 36798825
63. Trama A, Licitra L, **Cavalieri S**, Bonfarnuzzo S, Baili P, Ciarfella A, Parente P, Almadori G, Ansarin M, Bacigalupo A, Baumeister P, Baujat B, Bossi P, Cavallera E, Cercato MC, Dieleman F, Fakhry N, Ferraresi V, Gaino F, Galizia D, Haramkova J, Halme E, Hardillo J, Hofauer B, Kinloch E, Livi L, Locati LD, Mattheis S, Mercante G, Mirabile A, Molteni G, Orlandi E, Persio R, Sciallero S, Smele L, Tagliabue M, Valentini V, Van Harpen C, Westphalen CB, Botta L. The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers. *PLoS One*. 2023 Mar 16;18(3):e0283071. doi: 10.1371/journal.pone.0283071. eCollection 2023. PMID: 36928072
64. **Cavalieri S**, Vitolo V, Barcellini A, Ronchi S, Facchetti A, Campo C, Klersy C, Molinelli S, Agustoni F, Ferretti VV, Silvestri A, Platania M, Vecchio MD, Durante M, Helm A, Fournier C, Braud F, Pedrazzoli P, Orlandi E, Licitra L. Immune checkpoint inhibitors and Carbon ion radiotherapy in solid Cancers with stable disease (ICONIC). *Future Oncol*. 2023 Jan;19(3):193-203. doi: 10.2217/fon-2022-0503. Epub 2023 Mar 28. PMID: 36974574
65. Bologna M, Corino V, **Cavalieri S**, Calareso G, Eleonora Gazzani S, Poli T, Ravanelli M, Mattavelli D, de Graaf P, Nauta I, Scheckenbach K, Licitra L, Mainardi L. Prognostic radiomic signature for head and neck cancer: development and validation on a multi-centric MRI dataset. *Radiother Oncol*. 2023 Jun;183:109638. doi: 10.1016/j.radonc.2023.109638. Epub 2023 Mar 31. PMID: 37004837
66. Corti A, De Cecco L, **Cavalieri S**, Lenoci D, Pistore F, Calareso G, Mattavelli D, de Graaf P, Leemans CR, Brakenhoff RH, Ravanelli M, Poli T, Licitra L, Corino V, Mainardi L. MRI-based radiomic prognostic signature for locally advanced oral cavity squamous cell carcinoma: development, testing and comparison with genomic prognostic signatures. *Biomark Res*. 2023 Jul 16;11(1):69. doi: 10.1186/s40364-023-00494-5. PMID: 37455307
67. Giannini L, Alliaia A, Cristofaro V, Incandela F, Pompilio M, Ottini A, **Cavalieri S**, Nuzzolese I, Iacovelli NA, Franceschini M, Deganello A. Radiation-Induced Oropharyngeal Squamous Cell Carcinoma: Case Report and Review of the Literature. *Curr Oncol*. 2023 Jul 14;30(7):6708-6719. doi: 10.3390/curroncol30070492. PMID: 37504352
68. Rota S, Quattrone P, Centonze G, Dagrada G, Ottini A, Colombo E, Nuzzolese I, Calareso G, Franceschini M, Iacovelli NA, Perrone F, Tamborini E, **Cavalieri S**. NUT carcinoma of the submandibular gland: A case report. *Cancer Rep (Hoboken)*. 2023 Dec;6(12):e1900. doi: 10.1002/cnr.21900. Epub 2023 Sep 8. PMID: 37680121
69. Botta L, Matsuda T, Charvat H, Chiang CJ, Lee WC, van Gestel AJ, Martin F, Geleijnse G, Cellamare M, Bonfarnuzzo S, Marcos-Gragera R, Guevara M, Mousavi M, Craig S, Rodrigues J, Rubió-Casadevall J, Licitra L, **Cavalieri S**, Resteghini C, Gatta G, Trama A; RARECAREnet working group. Head and neck cancers survival in Europe, Taiwan, and Japan: results from RARECAREnet Asia based on a privacy-preserving federated infrastructure. *Front Oncol*. 2023 Sep 13;13:1219111. doi: 10.3389/fonc.2023.1219111. eCollection 2023. PMID: 37781187
70. **Cavalieri S**, Platini F, Barretta F, Nuzzolese I, Ottini A, Bergamini C, Resteghini C, Colombo E, Iacovelli NA, Franceschini M, Calareso G, Di Pede P, De Feo G, Gandelli M, Toffolatti L, Guglielmo M, Ripamonti CI, Cosmai L, Licitra L, Alfieri S. Pre-treatment risk factors to predict early cisplatin-related nephrotoxicity in locally advanced head and neck cancer patients treated with chemoradiation: A single Institution experience. *Oral Oncol*. 2023 Nov;146:106579. doi: 10.1016/j.oraloncology.2023.106579. Epub 2023 Sep 29. PMID: 37778228
71. **Cavalieri S**, Bergamini C, Alfieri S, Resteghini C, Nuzzolese I, Colombo E, Ottini A, Licitra L. Management of patients with skin adnexal carcinomas. *EJC Skin Cancer*. 2023; 1, 100006. doi: 10.1016/j.ejcskn.2023.100006
72. Lenoci D, Resteghini C, Serafini MS, Pistore F, Canevari S, Ma B, **Cavalieri S**, Alfieri S, Trama A, Licitra L, De Cecco L. Tumor molecular landscape of Epstein-Barr virus (EBV) related nasopharyngeal carcinoma in EBV-endemic and non-endemic areas: implications for improving treatment modalities. *Transl Res*. 2024 Mar;265:1-16. doi: 10.1016/j.trsl.2023.10.004. Epub 2023 Nov 8. PMID: 37949350
73. Hernández L, Estévez-Priego E, López-Pérez L, Cabrera-Umpiérrez MF, Arredondo MT, Fico G; BD2Decide Consortium (Poli T, Rossi S, Martinelli E, Licitra L, **Cavalieri S**, De Cecco L, Canevari S, Scheckenbach K, Brakenhoff RH, Nauta I, Hoebbers FJP, Wesseling FWR, Trama A, Gatta G). HeNeCon: An ontology for integrative research in Head and Neck cancer. *Int J Med Inform*. 2024 Jan;181:105284. doi: 10.1016/j.ijmedinf.2023.105284. Epub 2023 Nov 8. PMID: 37981440
74. Bergamini C, **Cavalieri S***, Resteghini C, Alfieri S, Nuzzolese I, Colombo E, Ottini A, Calareso G, Vingiani A, Iacovelli NA, Franceschini M, Guzzo M, Deganello A, Licitra L. Multidisciplinary management of pregnancy-associated and early post-partum head and neck cancer patients. *Front Oncol*. 2023 Nov 22;13:1298439. doi: 10.3389/fonc.2023.1298439. eCollection 2023. PMID: 38074678
75. Alfieri S, Romanò R, Marcegaglia S, De Giorgi V, Peris K, Sollena P, Piccerillo A, Moro R, Gualdi G, Ascierto PA, Palla M,

- Paone M, Eibenschutz L, Spagnolo F, Queirolo P, Filippini DM, **Cavalieri S**, Resteghini C, Bergamini C, Manocchio A, Licitra L, Bossi P. Hedgehog Inhibitors Beyond Clinical Complete Response in Basal Cell Carcinoma: Should I Stop or Should I Go? *Oncologist*. 2023 Dec 21;oyad319. doi: 10.1093/oncolo/oyad319. Online ahead of print. PMID: 38127280
76. Vallacchi V, Vergani E, Cossa M, Gargiuli C, Busico A, Devecchi A, Dugo M, Bergamaschi L, De Cecco L, **Cavalieri S**, Valeri B, Tamborini E, Gallino G, Del Vecchio M, Santinami M, Sensi M, Rivoltini L, Di Guardo L, Rodolfo M. Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case. *J Immunother Cancer*. 2024 Jan 4;12(1):e007612. doi: 10.1136/jitc-2023-007612. PMID: 38177075
 77. **Cavalieri S**, Bruno E, Serafini MS, Lenoci D, Canevari S, Lopez-Perez L, Hernandez L, Mariani L, Miceli R, Gavazzi C, Pasanisi P, Rosso E, Cordero F, Bossi P, Golusinski W, Dietz A, Strojan P, Fuereder T, De Cecco L, Licitra L. Dietary intervention for tertiary prevention in head and neck squamous cell carcinoma survivors: clinical and translational results of a randomized phase II trial. *Front Oncol*. 2024 Jan 4;13:1321174. doi: 10.3389/fonc.2023.1321174. eCollection 2023. PMID: 38239654
 78. Serafini MS, **Cavalieri S***, Licitra L, Pistore F, Lenoci D, Canevari S, Airoidi M, Cossu Rocca M, Strojan P, Kuhar CG, Merlano M, Perrone F, Vingiani A, Denaro N, Perri F, Argiris A, Gurizzan C, Ghi MG, Cassano A, Allegrini G, Bossi P, De Cecco L. Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. *J Immunother Cancer*. 2024 Jan 30;12(1):e007823. doi: 10.1136/jitc-2023-007823. PMID: 38290766
 79. Nuzzolese I, Bonomo P, Orlandi E, Mock A, **Cavalieri S**. Editorial: Diagnosis, epidemiology and treatment of salivary gland carcinomas. *Front Oncol*. 2024 Feb 20;14:1379584. doi: 10.3389/fonc.2024.1379584. eCollection 2024. PMID: 38444676
 80. Corti A, **Cavalieri S**, Calareso G, Mattavelli D, Ravanelli M, Poli T, Licitra L, Corino VDA, Mainardi L. MRI radiomics in head and neck cancer from reproducibility to combined approaches. *Sci Rep*. 2024 Apr 24;14(1):9451. doi: 10.1038/s41598-024-60009-6. PMID: 38658630
 81. Licitra L, **Cavalieri S**, Tinelli C, Franzetti J, Orlandi E. Developing a trial design to establish BNCT as clinical application: insight for the national Italian center for oncological hadrontherapy (CNAO). *Health and Technology (2024) 14*:1037–1041. doi: 10.1007/s12553-024-00839-6
 82. **Cavalieri S**, Bergamini C, Lenoci D, Ottini A, Lucchetta M, Torchia E, Licitra L, De Cecco L. Claudin-1 in Head and Neck Squamous Cell Carcinoma. *Oncology*. 2024 Aug 14;1-5. doi: 10.1159/000540775. PMID: 39231459
 83. Lenoci D, Moresco E, **Cavalieri S**, Bergamini C, Torchia E, Botta L, Canevari S, Trama A, Licitra L, De Cecco L. Oral cancer in young adults: incidence, risk factors, prognosis, and molecular biomarkers. *Front Oncol*. 2024 Sep 20;14:online ahead of print. doi: 10.3389/fonc.2024.1452909
 84. Prost D, Iseas S, Gatineau M, Adam J, **Cavalieri S**, Bergamini C, Licitra L, Raymond É. Systemic treatments in recurrent or metastatic salivary gland cancer: a systematic review. *ESMO Open*. 2024 Oct 4;9(10):103722. doi: 10.1016/j.esmoop.2024.103722. Online ahead of print. PMID: 39368417
 85. Lenoci D, Serafini MS, Lucchetta M, **Cavalieri S**, Brakenhoff RH, Hoebbers F, Scheckenbach K, Poli T, Licitra L, De Cecco L. Ferroptosis-Related Gene Signatures: Prognostic Role in HPV-Positive Oropharyngeal Squamous Cell Carcinoma. *Cancers* 2025, 17, 530. doi: 10.3390/cancers17030530
 86. Bossi P, Alberti A, Bergamini C, Resteghini C, Locati LD, Alfieri S, **Cavalieri S**, Colombo E, Gurizzan C, Lorini L, Tovazzi V, Zamparini M, Ravanelli M, Ascierto PA, Rampinelli V, Grammatica A, Patuzzo R, Maurichi A, Licitra LF. Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial. *Eur J Cancer*. 2025 Mar 23;220:115379. doi: 10.1016/j.ejca.2025.115379. Online ahead of print. PMID: 40154210
 87. Corti A, Lenoci D, Corino VDA, Mattavelli D, Ravanelli M, Poli T, **Cavalieri S**, Licitra L, De Cecco L, Mainardi L. Interplay between MRI radiomics and immune gene expression signatures in oral squamous cell carcinoma. *Sci Rep*. 2025 Apr 12;15(1):12622. doi: 10.1038/s41598-025-96821-x. PMID: 40221527
 88. **Cavalieri S**, Brakenhoff RH, Leemans CR, Hoebbers FJP, Poli T, Scheckenbach K, Iacovelli NA, Franceschini M, Orlandi E, Licitra L, De Cecco L. Prognostic Gene Expression Signatures for HPV-Negative Head and Neck Squamous Cell Carcinoma. Accepted for publication in *Radiotherapy & Oncology* on April 16th 2025. Ahead of print

* co-first author

ADDITIONAL INFORMATION

Bibliometrics

ORCID: 0000-0003-1294-6859

Scopus ID: 57191971361

Web of Science ResearcherID: AAB-3879-2019

- Certifications**
- 12/2023 National scientific qualification to function as associate professor in Italian Universities (ASN, Abilitazione Scientifica Nazionale), sector MED/06 - Oncology
 - 10/2023 ESMO Medical Oncologist's Recertification Approval (MORA)
 - 10/2022 & 11/2024 BLSD (Basic Life Support Defibrillation) retraining
 - 11/2021 ACLS (Advanced Cardiovascular Life Support)
 - 10/2018 ESMO Examination for Medical Oncologists
 - 02/2018 University Post-graduate Course, Clinical Oncology: Head & neck cancers - University of Milan, Milano (Italy) - European School of Oncology
- Memberships**
- AIOCC (Italian Association of Head and Neck Oncology) since 2021
 - Internal Review Board of the Scientific Direction of the Fondazione IRCCS Istituto Nazionale dei Tumori di Milano since 2021
 - EORTC (European Organisation for Research and Treatment of Cancer) since 2021
 - AIOM (Italian Society of Medical Oncology) since 2016
 - ESMO (European Society for Medical Oncology) since 2016

Il sottoscritto è a conoscenza che, ai sensi dell'art. art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali ai sensi dell'art. 13 GDPR 679/16 – “Regolamento europeo sulla protezione dei dati personali”.

Milan, April 16th 2025